CANADIAN BURDEN OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA: FINAL RESULTS

被引：0
|
作者：
Zaour, N. [1 ]
Heisel, O. [2 ]
Leteneux, C. [3 ]
Ma, P. [4 ]
机构：
[1] Novartis Pharmaceut Canada Inc, Dorval, PQ, Canada
[2] Syreon Corp, Vancouver, BC, Canada
[3] Novartis Pharma AG, Basel, Switzerland
[4] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.1657
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS10
引用
收藏
页码：A284 / A285
页数：2
相关论文
共 50 条
  • [11] Efficacy of Conbercept in the Treatment of Choroidal Neovascularization Secondary to Pathologic Myopia
    Lu, Hui
    Yue, Tao
    Liu, Na
    Wang, Zuo-Fen
    Zhai, Gai-Xia
    Mi, Dong-Ming
    Zhang, Jing
    Wang, Shao-Peng
    FRONTIERS IN MEDICINE, 2021, 8
  • [12] INTRAVITREAL BEVACIZUMAB FOR EXTRAFOVEAL CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA
    Parodi, Maurizio B.
    Iacono, Pierluigi
    Papayannis, Alessandro
    Kontadakis, Stylianos
    Cascavilla, Maria L.
    Zucchiatti, Ilaria
    Bandello, Francesco
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2013, 33 (03): : 593 - 597
  • [13] OCT-ANGIOGRAPHY OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA
    Giuffre, Chiara
    Querques, Lea
    Corvi, Federico
    Zucchiatti, Ilaria
    Mazzaferro, Andrea
    Tomasso, Livia
    Corbelli, Eleonora
    Carnevali, Adriano
    Querques, Giuseppe
    Bandello, Francesco
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [14] Bevacizumab suppresses choroidal neovascularization secondary to pathologic myopia: A pilot study
    Nguyen, QD
    Shah, SM
    Tatlipinar, S
    Do, DV
    Van Anden, E
    Campochiaro, PA
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46
  • [15] INTRAVITREAL RANIBIZUMAB FOR THE PRIMARY TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA
    Lai, Timothy Y. Y.
    Chan, Wai-Man
    Liu, David T. L.
    Lam, Dennis S. C.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2009, 29 (06): : 750 - 756
  • [16] Three Years Follow-up Results of Ranibizumab Treatment for Choroidal Neovascularization Secondary to Pathologic Myopia
    Hefner, L.
    Riese, J.
    Gerding, H.
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2013, 230 (04) : 401 - 404
  • [17] Characteristics of Periconus Choroidal Neovascularization in Pathologic Myopia
    Nagaoka, Natsuko
    Shimada, Noriaki
    Hayashi, Wakako
    Hayashi, Kengo
    Moriyama, Muka
    Yoshida, Takeshi
    Tokoro, Takashi
    Ohno-Matsui, Kyoko
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2011, 152 (03) : 420 - 427
  • [18] Results of Ranibizumab Treatment for Choroidal Neovascularization Secondary to Pathological Myopia
    Hefner, L.
    Riese, J.
    Gerding, H.
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2011, 228 (04) : 284 - 287
  • [19] Circulating hematopoietic stem cells in patients with choroidal neovascularization secondary to pathologic myopia
    Sasahara, M.
    Otani, A.
    Yodoi, Y.
    Gotoh, N.
    Kameda, T.
    Yoshimura, N.
    EYE, 2009, 23 (03) : 718 - 726
  • [20] Circulating hematopoietic stem cells in patients with choroidal neovascularization secondary to pathologic myopia
    M Sasahara
    A Otani
    Y Yodoi
    N Gotoh
    T Kameda
    N Yoshimura
    Eye, 2009, 23 : 718 - 726
12345